Winton Group LTD Apellis Pharmaceuticals, Inc. Transaction History

Winton Group LTD

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $323,077 - $502,805	7,218 New	7,218 $493,000
Q2 2022 Aug 10, 2022	SELL	$35.07 - $59.21 $348,280 - $588,014	-9,931 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$35.46 - $54.12 $352,153 - $537,465	9,931 New	9,931 $505,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.